MICRO-X LIMITED (MX1)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MX1

MX1 - MICRO-X LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.31
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.08

21 Aug
2025

0.000

OPEN

$0.08

0.000

HIGH

$0.08

246,446

LOW

$0.08

TARGET
$0.17 112.5% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
MX1: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 1.8 - 1.3 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-1.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx15.2 M
Book Value Per Share xxxxxxxxxxxxxxx2.4
Net Operating Cash Flow xxxxxxxxxxxxxxx-6.4 M
Net Profit Margin xxxxxxxxxxxxxxx-64.15 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-62.35 %
Return on Invested Capital xxxxxxxxxxxxxxx-50.43 %
Return on Assets xxxxxxxxxxxxxxx-34.15 %
Return on Equity xxxxxxxxxxxxxxx-62.35 %
Return on Total Capital xxxxxxxxxxxxxxx-72.97 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-6.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx3 M
Total Debt xxxxxxxxxxxxxxx4 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx3 M
Price To Book Value xxxxxxxxxxxxxxx3.40

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.4 M
Capex % of Sales xxxxxxxxxxxxxxx2.42 %
Cost of Goods Sold xxxxxxxxxxxxxxx24 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx6 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

01/08/2025

1

Speculative Buy

$0.17

112.50%

Morgans highlights Micro-X has announced a three-year supply agreement for its Rover Plus mobile radiology system with a major US healthcare provider with over 700 facilities. This is the first supply agreement for the company with a major US healthcare company.

The analyst also points to 4Q25 cashflow, with some customer receipts of $0.8m, for a total of $2.8m year-to-date. Project work on the medical side was $1.4m, or $3.7m year-to-date, and security contracts came in at $1.4m, or $6.8m year-to-date.

Net operating cashflow of $3.5m for the quarter and $8.5m year-to-date resulted in cash at end of FY25 of $3.2m.

Speculative Buy rating and 17c target unchanged. No changes to Morgans' earnings forecasts. Micro-X is due to report FY25 results on August 27.

FORECAST
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.30 cents.
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.90 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

MX1 STOCK CHART

FNArena News on MX1

1
FNArena Corporate Results Monitor – 29-02-2024

Feb 29 2024 - Australia
2
Dr Boreham’s Crucible: Argenica Therapeutics

Sep 28 2023 - Small Caps
3
FNArena Corporate Results Monitor – 31-08-2023

Aug 31 2023 - Australia
4
FNArena Corporate Results Monitor – 28-02-2023

Feb 28 2023 - Australia
5
FNArena Corporate Results Monitor – 31-08-2022

Aug 31 2022 - Australia

Latest Medical Equipment & Devices News

1
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
2
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
3
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
4
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia
5
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
6
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
7
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
8
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
9
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
10
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia